{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:54:54Z","timestamp":1794567294886,"version":"4.9.1"},"publisher-location":"New York, NY","reference-count":75,"publisher":"Springer New York","isbn-type":[{"value":"9781493978243","type":"print"},{"value":"9781493978250","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-1-4939-7825-0_21","type":"book-chapter","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T08:44:16Z","timestamp":1527756256000},"page":"463-481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["CRISPR\/Cas9-Mediated Genome Editing for Huntington\u2019s Disease"],"prefix":"10.1007","author":[{"given":"Gabriel","family":"Vachey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"D\u00e9glon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"21_CR1","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","volume":"157","author":"PD Hsu","year":"2014","unstructured":"Hsu PD, Lander ES, Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. Cell 157:1262\u20131278","journal-title":"Cell"},{"key":"21_CR2","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nrg2842","volume":"11","author":"FD Urnov","year":"2010","unstructured":"Urnov FD, Rebar EJ, Holmes MC et al (2010) Genome editing with engineered zinc finger nucleases. Nat Rev Genet 11:636\u2013646","journal-title":"Nat Rev Genet"},{"key":"21_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.14802\/jmd.16029","volume":"9","author":"W Im","year":"2016","unstructured":"Im W, Moon J, Kim M (2016) Applications of CRISPR\/Cas9 for gene editing in hereditary movement disorders. J Mov Disord 9:136\u2013143","journal-title":"J Mov Disord"},{"key":"21_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13059-015-0824-9","volume":"16","author":"RD Fagerlund","year":"2015","unstructured":"Fagerlund RD, Staals RH, Fineran PC (2015) The Cpf1 CRISPR-Cas protein expands genome-editing tools. Genome Biol 16:251","journal-title":"Genome Biol"},{"key":"21_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature14299","volume":"520","author":"FA Ran","year":"2015","unstructured":"Ran FA, Cong L, Yan WX et al (2015) In vivo genome editing using Staphylococcus aureus Cas9. Nature 520:186\u2013191","journal-title":"Nature"},{"key":"21_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13578-015-0027-9","volume":"5","author":"SM Riordan","year":"2015","unstructured":"Riordan SM, Heruth DP, Zhang LQ, Ye SQ (2015) Application of CRISPR\/Cas9 for biomedical discoveries. Cell Biosci 5:33","journal-title":"Cell Biosci"},{"key":"21_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.tcb.2016.08.004","volume":"26","author":"F Wang","year":"2016","unstructured":"Wang F, Qi LS (2016) Applications of CRISPR genome engineering in cell biology. Trends Cell Biol 26:875\u2013888","journal-title":"Trends Cell Biol"},{"key":"21_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1146\/annurev-genet-051710-150955","volume":"44","author":"WD Heyer","year":"2010","unstructured":"Heyer WD, Ehmsen KT, Liu J (2010) Regulation of homologous recombination in eukaryotes. Annu Rev Genet 44:113\u2013139","journal-title":"Annu Rev Genet"},{"key":"21_CR9","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J et\u00a0al (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8:2281\u20132308","journal-title":"Nat Protoc"},{"key":"21_CR10","first-page":"362","volume":"6","author":"BJ Walters","year":"2015","unstructured":"Walters BJ, Azam AB, Gillon CJ et al (2015) Advanced in vivo use of CRISPR\/Cas9 and anti-sense DNA inhibition for gene manipulation in the brain. Front Genet 6:362","journal-title":"Front Genet"},{"key":"21_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates GP, Dorsey R, Gusella JF et al (2015) Huntington disease. Nat Rev Dis Primers 1:15005","journal-title":"Nat Rev Dis Primers"},{"key":"21_CR12","first-page":"10","volume":"13","author":"A Smith","year":"2016","unstructured":"Smith A, Zanardi T, Norris D et al (2016) Antisense oligonucleotides enter clinical trials. HD Insights 13:10\u201315","journal-title":"HD Insights"},{"key":"21_CR13","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/mt.2009.17","volume":"17","author":"RL Boudreau","year":"2009","unstructured":"Boudreau RL, McBride JL, Martins I et al (2009) Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington\u2019s disease mice. Mol Ther 17:1053\u20131063","journal-title":"Mol Ther"},{"key":"21_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/ana.21569","volume":"65","author":"V Drouet","year":"2009","unstructured":"Drouet V, Perrin V, Hassig R et al (2009) Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol 65:276\u2013285","journal-title":"Ann Neurol"},{"key":"21_CR15","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1073\/pnas.1524575113","volume":"113","author":"G Wang","year":"2016","unstructured":"Wang G, Liu X, Gaertig MA et al (2016) Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc Natl Acad Sci U S A 113:3359\u20133364","journal-title":"Proc Natl Acad Sci U S A"},{"key":"21_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/cge.12385","volume":"86","author":"C Kay","year":"2014","unstructured":"Kay C, Skotte NH, Southwell AL, Hayden MR (2014) Personalized gene silencing therapeutics for Huntington disease. Clin Genet 86:29\u201336","journal-title":"Clin Genet"},{"key":"21_CR17","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ajhg.2012.01.005","volume":"90","author":"JM Lee","year":"2012","unstructured":"Lee JM, Gillis T, Mysore JS et al (2012) Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. Am J Hum Genet 90:434\u2013444","journal-title":"Am J Hum Genet"},{"key":"21_CR18","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ajhg.2015.07.017","volume":"97","author":"JM Lee","year":"2015","unstructured":"Lee JM, Kim KH, Shin A et al (2015) Sequence-level analysis of the major European Huntington disease haplotype. Am J Hum Genet 97:435\u2013444","journal-title":"Am J Hum Genet"},{"key":"21_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ajhg.2009.02.003","volume":"84","author":"SC Warby","year":"2009","unstructured":"Warby SC, Montpetit A, Hayden AR et al (2009) CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet 84:351\u2013366","journal-title":"Am J Hum Genet"},{"key":"21_CR20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/ejhg.2010.229","volume":"19","author":"SC Warby","year":"2011","unstructured":"Warby SC, Visscher H, Collins JA et al (2011) HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. Eur J Hum Genet 19:561\u2013566","journal-title":"Eur J Hum Genet"},{"key":"21_CR21","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.molmed.2012.09.001","volume":"18","author":"AL Southwell","year":"2012","unstructured":"Southwell AL, Skotte NH, Bennett CF, Hayden MR (2012) Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends Mol Med 18:634\u2013643. \nhttps:\/\/doi.org\/10.1016\/j.molmed.2012.09.001","journal-title":"Trends Mol Med"},{"key":"21_CR22","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/mds.26020","volume":"29","author":"N Aronin","year":"2014","unstructured":"Aronin N, DiFiglia M (2014) Huntingtin-lowering strategies in Huntington\u2019s disease: antisense oligonucleotides, small RNAs, and gene editing. Mov Disord 29:1455\u20131461","journal-title":"Mov Disord"},{"key":"21_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099341","volume":"9","author":"V Drouet","year":"2014","unstructured":"Drouet V, Ruiz M, Zala D et al (2014) Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells. PLoS One 9:e99341","journal-title":"PLoS One"},{"key":"21_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107434","volume":"9","author":"NH Skotte","year":"2014","unstructured":"Skotte NH, Southwell AL, Ostergaard ME et al (2014) Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. PLoS One 9:e107434","journal-title":"PLoS One"},{"key":"21_CR25","first-page":"4566","volume":"25","author":"JW Shin","year":"2016","unstructured":"Shin JW, Kim KH, Chao MJ et al (2016) Permanent inactivation of Huntington\u2019s disease mutation by personalized allele-specific CRISPR\/Cas9. Hum Mol Genet 25:4566\u20134576","journal-title":"Hum Mol Genet"},{"key":"21_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","volume":"25","author":"AM Monteys","year":"2017","unstructured":"Monteys AM, Ebanks SA, Keiser MS, Davidson BL (2017) CRISPR\/Cas9 editing of the mutant huntingtin allele in vitro and in vivo. Mol Ther 25:12\u201323","journal-title":"Mol Ther"},{"key":"21_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jconrel.2016.11.014","volume":"244","author":"J Liu","year":"2016","unstructured":"Liu J, Shui SL (2016) Delivery methods for site-specific nucleases: achieving the full potential of therapeutic gene editing. J Control Release 244:83\u201397","journal-title":"J Control Release"},{"key":"21_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17050626","volume":"17","author":"L Wang","year":"2016","unstructured":"Wang L, Li F, Dang L et al (2016) In vivo delivery systems for therapeutic genome editing. Int J Mol Sci 17:pii.E626","journal-title":"Int J Mol Sci"},{"key":"21_CR29","series-title":"Neuromethods","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/978-1-62703-610-8_11","volume-title":"Viral vector approaches in neurobiology and brain diseases book series","author":"A Delzor","year":"2014","unstructured":"Delzor A, Dufour N, Deglon N (2014) Lentiviral vectors in Huntington\u2019s disease research and therapy. In: Brambilla R (ed) Viral vector approaches in neurobiology and brain diseases book series, Neuromethods, vol 82. Humana Press, Totowa NJ, pp 193\u2013220"},{"key":"21_CR30","volume":"57","author":"C McClure","year":"2011","unstructured":"McClure C, Cole KL, Wulff P et al (2011) Production and titering of recombinant adeno-associated viral vectors. J Vis Exp 57:e3348","journal-title":"J Vis Exp"},{"key":"21_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2016.17","volume":"3","author":"OW Merten","year":"2016","unstructured":"Merten OW, Hebben M, Bovolenta C (2016) Production of lentiviral vectors. Mol Ther Methods Clin Dev 3:16017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"21_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nmeth.3284","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim D, Bae S, Park J et\u00a0al (2015) Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat Methods 12:237\u2013243","journal-title":"Nat Methods"},{"key":"21_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aad5227","volume":"351","author":"IM Slaymaker","year":"2016","unstructured":"Slaymaker IM, Gao L, Zetsche B et al (2016) Rationally engineered Cas9 nucleases with improved specificity. Science 351:84\u201388","journal-title":"Science"},{"key":"21_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nbt.3117","volume":"33","author":"SQ Tsai","year":"2015","unstructured":"Tsai SQ, Zheng Z, Nguyen NT et al (2015) GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol 33:187\u2013197","journal-title":"Nat Biotechnol"},{"key":"21_CR35","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/nbt.3026","volume":"32","author":"JG Doench","year":"2014","unstructured":"Doench JG, Hartenian E, Graham DB et al (2014) Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol 32:1262\u20131267","journal-title":"Nat Biotechnol"},{"key":"21_CR36","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nbt.2647","volume":"31","author":"PD Hsu","year":"2013","unstructured":"Hsu PD, Scott DA, Weinstein JA et al (2013) DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31:827\u2013832","journal-title":"Nat Biotechnol"},{"key":"21_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nbt.2808","volume":"32","author":"Y Fu","year":"2014","unstructured":"Fu Y, Sander JD, Reyon D et al (2014) Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol 32:279\u2013284","journal-title":"Nat Biotechnol"},{"key":"21_CR38","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.molcel.2016.07.004","volume":"63","author":"J Tycko","year":"2016","unstructured":"Tycko J, Myer VE, Hsu PD (2016) Methods for optimizing CRISPR-Cas9 genome editing specificity. Mol Cell 63:355\u2013370","journal-title":"Mol Cell"},{"key":"21_CR39","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/nmeth.3624","volume":"12","author":"MF Bolukbasi","year":"2015","unstructured":"Bolukbasi MF, Gupta A, Oikemus S et al (2015) DNA-binding-domain fusions enhance the targeting range and precision of Cas9. Nat Methods 12:1150\u20131156","journal-title":"Nat Methods"},{"key":"21_CR40","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.1232033","volume":"339","author":"P Mali","year":"2013","unstructured":"Mali P, Yang L, Esvelt KM et al (2013) RNA-guided human genome engineering via Cas9. Science 339:823\u2013826","journal-title":"Science"},{"key":"21_CR41","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cell.2015.09.038","volume":"163","author":"B Zetsche","year":"2015","unstructured":"Zetsche B, Gootenberg JS, Abudayyeh OO et al (2015) Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 163:759\u2013771","journal-title":"Cell"},{"key":"21_CR42","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ab.2016.10.018","volume":"532","author":"FA Ran","year":"2016","unstructured":"Ran FA (2016) Adaptation of CRISPR nucleases for eukaryotic applications. Anal Biochem 532:90\u201394","journal-title":"Anal Biochem"},{"key":"21_CR43","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench JG, Fusi N, Sullender M et al (2016) Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol 34:184\u2013191","journal-title":"Nat Biotechnol"},{"key":"21_CR44","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana NE, Shalem O, Zhang F (2014) Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods 11:783\u2013784","journal-title":"Nat Methods"},{"key":"21_CR45","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1089\/hum.2010.245","volume":"22","author":"SJ Gray","year":"2011","unstructured":"Gray SJ, Foti SB, Schwartz JW et al (2011) Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther 22:1143\u20131153","journal-title":"Hum Gene Ther"},{"key":"21_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku749","volume":"42","author":"AM Kabadi","year":"2014","unstructured":"Kabadi AM, Ousterout DG, Hilton IB, Gersbach CA (2014) Multiplex CRISPR\/Cas9-based genome engineering from a single lentiviral vector. Nucleic Acids Res 42:e147","journal-title":"Nucleic Acids Res"},{"key":"21_CR47","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong L, Ran FA, Cox D et al (2013) Multiplex genome engineering using CRISPR\/Cas systems. Science 339:819\u2013823","journal-title":"Science"},{"key":"21_CR48","doi-asserted-by":"publisher","unstructured":"Bauer DE, Canver MC, Orkin SH (2015) Generation of genomic deletions in mammalian cell lines via CRISPR\/Cas9. J Vis Exp:e52118. \nhttps:\/\/doi.org\/10.3791\/52118","DOI":"10.3791\/52118"},{"key":"21_CR49","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature13902","volume":"516","author":"D Maddalo","year":"2014","unstructured":"Maddalo D, Manchado E, Concepcion CP et al (2014) In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR\/Cas9 system. Nature 516:423\u2013427. \nhttps:\/\/doi.org\/10.1038\/nature13902","journal-title":"Nature"},{"key":"21_CR50","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1534\/g3.114.015834","volume":"5","author":"L Vouillot","year":"2015","unstructured":"Vouillot L, Thelie A, Pollet N (2015) Comparison of T7E1 and surveyor mismatch cleavage assays to detect mutations triggered by engineered nucleases. G3 5:407\u2013415","journal-title":"G3"},{"key":"21_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku936","volume":"42","author":"EK Brinkman","year":"2014","unstructured":"Brinkman EK, Chen T, Amendola M, van Steensel B (2014) Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res 42:e168","journal-title":"Nucleic Acids Res"},{"key":"21_CR52","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/nbt.3583","volume":"34","author":"L Pinello","year":"2016","unstructured":"Pinello L, Canver MC, Hoban MD et al (2016) Analyzing CRISPR genome-editing experiments with CRISPResso. Nat Biotechnol 34:695\u2013697","journal-title":"Nat Biotechnol"},{"key":"21_CR53","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.stem.2014.06.011","volume":"15","author":"C Smith","year":"2014","unstructured":"Smith C, Gore A, Yan W et al (2014) Whole-genome sequencing analysis reveals high specificity of CRISPR\/Cas9 and TALEN-based genome editing in human iPSCs. Cell Stem Cell 15:12\u201313","journal-title":"Cell Stem Cell"},{"key":"21_CR54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.stem.2014.04.020","volume":"15","author":"A Veres","year":"2014","unstructured":"Veres A, Gosis BS, Ding Q et al (2014) Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell 15:27\u201330","journal-title":"Cell Stem Cell"},{"key":"21_CR55","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nmeth.2408","volume":"10","author":"N Crosetto","year":"2013","unstructured":"Crosetto N, Mitra A, Silva MJ et al (2013) Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing. Nat Methods 10:361\u2013365","journal-title":"Nat Methods"},{"key":"21_CR56","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13059-015-0846-3","volume":"16","author":"Y Dang","year":"2015","unstructured":"Dang Y, Jia G, Choi J, Ma H et al (2015) Optimizing sgRNA structure to improve CRISPR-Cas9 knockout efficiency. Genome Biol 16:280","journal-title":"Genome Biol"},{"key":"21_CR57","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1101\/gr.162339.113","volume":"24","author":"SW Cho","year":"2014","unstructured":"Cho SW, Kim S, Kim Y et al (2014) Analysis of off-target effects of CRISPR\/Cas-derived RNA-guided endonucleases and nickases. Genome Res 24:132\u2013141","journal-title":"Genome Res"},{"key":"21_CR58","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nature16526","volume":"529","author":"BP Kleinstiver","year":"2016","unstructured":"Kleinstiver BP, Pattanayak V, Prew MS et al (2016) High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529:490\u2013495","journal-title":"Nature"},{"key":"21_CR59","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nmeth.2857","volume":"11","author":"B Shen","year":"2014","unstructured":"Shen B, Zhang W, Zhang J et\u00a0al (2014) Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods 11:399\u2013402","journal-title":"Nat Methods"},{"key":"21_CR60","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0896-6273(00)80764-3","volume":"23","author":"JG Hodgson","year":"1999","unstructured":"Hodgson JG, Agopyan N, Gutekunst CA et al (1999) A YAC mouse model for Huntington\u2019s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23:181\u2013192","journal-title":"Neuron"},{"key":"21_CR61","doi-asserted-by":"publisher","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","volume":"28","author":"M Gray","year":"2008","unstructured":"Gray M, Shirasaki DI, Cepeda C et al (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28:6182\u20136195","journal-title":"J Neurosci"},{"key":"21_CR62","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/hmg\/dds397","volume":"22","author":"AL Southwell","year":"2013","unstructured":"Southwell AL, Warby SC, Carroll JB et al (2013) A fully humanized transgenic mouse model of Huntington disease. Hum Mol Genet 22:18\u201334","journal-title":"Hum Mol Genet"},{"key":"21_CR63","first-page":"1115","volume":"26","author":"AL Southwell","year":"2017","unstructured":"Southwell AL, Skotte NH, Villanueva EB et al (2017) A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles. Hum Mol Genet 26:1115\u20131132","journal-title":"Hum Mol Genet"},{"key":"21_CR64","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nbt.3055","volume":"33","author":"L Swiech","year":"2015","unstructured":"Swiech L, Heidenreich M, Banerjee A et al (2015) In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol 33:102\u2013106","journal-title":"Nat Biotechnol"},{"key":"21_CR65","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nbt0616-582","volume":"34","author":"E Waltz","year":"2016","unstructured":"Waltz E (2016) CRISPR-edited crops free to enter market, skip regulation. Nat Biotechnol 34:582","journal-title":"Nat Biotechnol"},{"key":"21_CR66","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nature.2016.19754","volume":"532","author":"E Waltz","year":"2016","unstructured":"Waltz E (2016) Gene-edited CRISPR mushroom escapes US regulation. Nature 532:293","journal-title":"Nature"},{"key":"21_CR67","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nature.2016.19270","volume":"530","author":"E Callaway","year":"2016","unstructured":"Callaway E (2016) BIOTECHNOLOGY Embryo editing gets green light. Nature 530:18","journal-title":"Nature"},{"key":"21_CR68","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/530402a","volume":"530","author":"EC Hayden","year":"2016","unstructured":"Hayden EC (2016) Tomorrow\u2019s children: what would genome editing really mean for future generations? Nature 530:402\u2013405","journal-title":"Nature"},{"key":"21_CR69","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nature.2017.21502","volume":"542","author":"H Ledford","year":"2017","unstructured":"Ledford H (2017) Court rules on CRISPR. Nature 542:401","journal-title":"Nature"},{"key":"21_CR70","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature.2016.20988","volume":"539","author":"D Cyranoski","year":"2016","unstructured":"Cyranoski D (2016) CRISPR gene-editing tested in a person for the first time. Nature 539:479","journal-title":"Nature"},{"key":"21_CR71","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature14592","volume":"523","author":"BP Kleinstiver","year":"2015","unstructured":"Kleinstiver BP, Prew MS, Tsai SQ et al (2015) Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 523:481\u2013485","journal-title":"Nature"},{"key":"21_CR72","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1038\/srep05400","volume":"4","author":"T Sakuma","year":"2014","unstructured":"Sakuma T, Nishikawa A, Kume S et al (2014) Multiplex genome engineering in human cells using all-in-one CRISPR\/Cas9 vector system. Sci Rep 4:5400","journal-title":"Sci Rep"},{"key":"21_CR73","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.1007\/s00018-016-2271-5","volume":"73","author":"J Vad-Nielsen","year":"2016","unstructured":"Vad-Nielsen J, Lin L, Bolund L et al (2016) Golden Gate Assembly of CRISPR gRNA expression array for simultaneously targeting multiple genes. Cell Mol Life Sci 73:4315\u20134325","journal-title":"Cell Mol Life Sci"},{"key":"21_CR74","doi-asserted-by":"publisher","first-page":"8101","DOI":"10.1038\/ncomms9101","volume":"6","author":"W Jiang","year":"2015","unstructured":"Jiang W, Zhao X, Gabrieli T et al (2015) Cas9-Assisted Targeting of CHromosome segments CATCH enables one-step targeted cloning of large gene clusters. Nat Commun 6:8101","journal-title":"Nat Commun"},{"key":"21_CR75","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2144\/000114261","volume":"58","author":"JW Wang","year":"2015","unstructured":"Wang JW, Wang A, Li K et al (2015) CRISPR\/Cas9 nuclease cleavage combined with Gibson assembly for seamless cloning. Biotechniques 58:161\u2013170","journal-title":"Biotechniques"}],"container-title":["Methods in Molecular Biology","Huntington\u2019s Disease"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-7825-0_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T09:08:51Z","timestamp":1532596131000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-7825-0_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9781493978243","9781493978250"],"references-count":75,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-7825-0_21","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-4939-7825-0","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}